MedTrace Logo

Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States

NCT02569307 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 326

Last updated 2019-08-05

No results posted yet for this study

Summary

This is a randomized double-blind placebo controlled trial which aims to evaluate the efficacy and tolerability of minocycline and Omega-3 fatty acids for patients with ARMS. Specifically to determine whether the addition of minocycline and / or Omega-3 fatty acids to Treatment as Usual in an operationalized ARMS population in Pakistan:

Conditions

Interventions

DRUG

Minocycline

Minocycline added to TAU Minocycline will be administered in 200mg once daily dose

DRUG

Omega-3 fatty acids

Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2g once daily dose

DRUG

Placebo

Placebo added to TAU

DRUG

Minocycline Plus Omega-3 fatty acids

Minocycline will be administered in 200mg once daily dose and Omega-3 fatty acid 1.2g taken as once daily dose

Sponsors & Collaborators

  • Pakistan Institute of Living and Learning

    lead OTHER

Principal Investigators

  • Dr.Inti Qurashi, MD · Manchester University ,UK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
FACTORIAL

Eligibility

Min Age
16 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-10-31
Primary Completion
2018-12-31
Completion
2019-03-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02569307 on ClinicalTrials.gov